Shares of NanoViricides, Inc. (NYSE:NNVC – Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $1.30 and traded as low as $1.2101. NanoViricides shares last traded at $1.23, with a volume of 171,037 shares changing hands.
NanoViricides Stock Performance
The company has a market cap of $31.40 million, a PE ratio of -1.71 and a beta of 1.82. The business’s 50-day moving average is $1.34 and its 200 day moving average is $1.30.
Institutional Investors Weigh In On NanoViricides
Hedge funds and other institutional investors have recently modified their holdings of the stock. Empowered Funds LLC purchased a new position in NanoViricides in the 3rd quarter worth approximately $46,000. Miller Financial Services LLC grew its holdings in shares of NanoViricides by 19.6% in the third quarter. Miller Financial Services LLC now owns 134,000 shares of the company’s stock worth $174,000 after purchasing an additional 22,000 shares during the last quarter. BlackRock Inc. bought a new position in shares of NanoViricides in the second quarter worth approximately $219,000. Finally, Connective Capital Management LLC bought a new position in shares of NanoViricides in the second quarter worth approximately $256,000. Institutional investors own 10.30% of the company’s stock.
About NanoViricides
NanoViricides, Inc. is a biotechnology company focused on developing antiviral treatments using its nanoviricide technology. The company’s approach is designed to target and bind to viruses, with the goal of neutralizing them or preventing them from infecting cells. The company’s research programs include NV-387, a candidate being developed for respiratory viral infections, as well as programs targeting other viruses, including herpesviruses and HIV. These candidates remain in development, and their availability as treatments depends on further research and regulatory review.
Further Reading
- Five stocks we like better than NanoViricides
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
